Serum Mindin, Nephrin and Podocalyxin Levels in Patients with Type 1 Diabetes: Are These New Markers to Detect the Development of Nephropathy?

Creative Commons License

Sambel I. T., EREN E., Bozyigit C., SARANDÖL E.

GUNCEL PEDIATRI-JOURNAL OF CURRENT PEDIATRICS, vol.20, no.2, pp.147-154, 2022 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.4274/jcp.2022.34635
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database
  • Page Numbers: pp.147-154
  • Keywords: Diabetes mellitus, mindin, podocalyxin, nephrin, diabetic nephropathy
  • Bursa Uludag University Affiliated: Yes


Introduction: Type 1 diabetes mellitus (DM) is a chronic disease that develops as a result of absolute insulin deficiency. DM is accompanied by chronic complications which are associated with a high risk of morbidity and mortality. In the present study, we aimed to understand whether serum mindin, nephrin (NPHS1) and podocalyxin (PODXL) are useful biomarkers in the determination of nephropathy in patients with type 1 DM and to understand any correlation between serum mindin, PODXL, nephrin levels and hemoglobin A1c (HbA1c) levels and 24 hour urinary albumin excretion of patients. We investigated serum PODXL, nephrin and mindin levels in pediatric patients with type 1 DM.